ジェイファーマ
520A・Growth Market・Pharmaceuticals
ジェイファーマ
520A・Growth Market・Pharmaceuticals
Business
J Pharma is a global drug discovery venture specializing in small-molecule drug discovery targeting L-type amino acid transporter 1 (LAT1), discovered by founder Jin Endou (Professor Emeritus, Kyorin University). Its mission is to address unmet medical needs in areas where existing treatments have proven insufficiently effective, such as cancer, autoimmune diseases, and rare diseases. The company is concurrently advancing a global Phase 3 clinical trial for biliary tract cancer (Beacon-BTC) using its lead compound Nanvuranlat (JPH203), and a U.S. Phase 1 clinical trial for non-relapsing secondary progressive multiple sclerosis using JPH034, a centrally-penetrant LAT1 inhibitor. Through close dialogue with the U.S. FDA, the company has built a global development framework in collaboration with CROs and academia in the U.S. and Europe.
Business Model
The Company currently records no revenue and adopts a drug discovery venture model in which R&D expenses are invested upfront. Its core path to monetization is to advance development in-house through global Phase 3 clinical trials and then conclude licensing agreements with pharmaceutical companies (upfront payments, milestones, and royalties), with an explicit strategy of avoiding value erosion from premature licensing. Funding is raised through equity issuance and public grants (AMED, NMSS, etc.), and the license agreement with Ohara Pharmaceutical Co., Ltd. for Japan and Asia (up to ¥550 million plus royalties of up to 10%) remains the only existing commercialization agreement to date.
Company Strengths
In the domestic Phase 2 clinical trial of Nanvuranlat (JPH203) (105 patients, randomized, double-blind), a PFS hazard ratio of 0.56 (p=0.02) was achieved, meeting the primary endpoint. The results were presented orally in two consecutive years at ASCO GI 2023 and the ASCO Annual Meeting 2023 (acceptance rate of only a few percent), and were published in Clinical Cancer Research. A safety profile with a Grade 3 or higher adverse event rate of 30%, substantially lower than existing therapies (FOLFOX at 69%, durvalumab combination at 76%), was also confirmed.
Orphan drug designation was obtained in April 2022, IND application approval was received in September 2024, and in May 2025 a positive written response was received from the FDA regarding CMC quality standard compliance at commercial manufacturing scale. It is rare for a program to advance to global Phase 3 through FDA review based on domestic clinical data, and this represents concrete evidence of the company's capability for regulatory dialogue and development execution.
For JPH034, the company obtained a global exclusive license to Georgetown University's patent covering LAT1 inhibitor use in central nervous system inflammatory diseases (including multiple sclerosis). It was also selected for the highly competitive NMSS Fast Forward Research Grant, receiving a grant of 600,000 US dollars. The program has also been selected for AMED's drug discovery venture ecosystem strengthening program, providing external scientific validation on both the intellectual property and funding fronts.
ENVALITH's Perspective
Performance Trend
In FY2026 (ending March 2026), business revenue was zero, with an operating loss of ¥3,710 million (vs. ¥1,596 million in the previous period) and a net loss of ¥2,466 million (vs. ¥1,499 million in the previous period), representing a substantial widening of losses. R&D expenses of ¥3,015 million accounted for 81.3% of total operating expenses, driven mainly by preparation for and initiation of the global Phase 3 trial for Nanvuranlat and Phase 1 preparation for JPH034. In financing activities, the company raised ¥4,334 million through share issuance, securing a period-end cash balance of ¥4,453 million. As a research and development-stage company with no revenue recognition, the widening loss reflects accelerated development progress, and the achievement status of clinical milestones—rather than financial metrics—remains the primary axis of corporate valuation.
Growth Strategy
Centered on global approval of Nanvuranlat and the conclusion of licensing agreements, the pipeline is being diversified with JPH034 and next-generation products
The Beacon-BTC trial (Part A: dose-finding, Part B: OS primary endpoint), initiated in December 2025, is being advanced according to plan, with the aim of obtaining global approval and achieving blockbuster status with annual sales of USD 1 billion. As of June 2026, progress is proceeding smoothly as planned.
Ongoing communication is being conducted with candidate partner companies for Nanvuranlat (12 companies) and JPH034 (13 companies). Based on progress in Beacon-BTC Part A, the company aims to build a commercialization scheme, including licensing agreements, from FY2028 (ending March 2028) onward.
The US Phase 1 clinical trial was initiated on March 22, 2026, and safety, tolerability, and pharmacokinetic data are being collected. With a view to reaching the stage where Phase 2 trials in the US and Europe can be conducted, the company aims to build a commercialization scheme in FY2027 (ending March 2027).
The company is concurrently advancing efforts to expand the indications of Nanvuranlat and JPH034, including a physician-initiated trial combining with ICI as first-line therapy for biliary tract cancer (JON-2404-B, registered with jRCT in April 2026), preparations to initiate a physician-initiated trial for KRAS-mutant colorectal cancer, nonclinical studies for rare diseases, and consideration of a clinical trial for glioma.
A candidate compound with characteristics equal to or superior to Nanvuranlat has been identified, and structural optimization and nonclinical evaluation are underway. As part of the Goals for 2030, the company aims to enter clinical trials by 2030.
Last updated: July 19, 2026